Current stock page

Financial Data

EXAS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - Diagnostics & ResearchScore data as of Sep 5, 2026

EXAS

Financial Data
Exact Sciences Corporation
Healthcare· Medical - Diagnostics & Research
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 5, 2026
Last price
Latest market quote
Momentum
Value37
Quality44
Risk Resilience67
Sentiment
View financial data

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Sep 5, 2026.

Income statement
8 periods
Metric2025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$878.38M$850.74M$811.09M$706.79M$713.42M$708.66M$699.26M$637.52M
Gross Profit$615.83M$583.93M$562.45M$500.55M$429.22M$512.56M$488.32M$446.32M
Operating Income
Net Income-$85.96M-$19.59M-$1.19M-$101.22M-$864.59M-$38.24M-$15.81M-$110.23M
EPS-$0.45-$0.1-$0.01-$0.54-$4.67-$0.21-$0.09-$0.6
Cash flow statement
8 periods
Metric2025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating Cash Flow$151.69M$219.92M$89.02M$30.81M$47.06M$138.72M$107.07M-$82.31M
Capital Expenditure-$31.24M-$29.9M-$42.34M-$31.17M-$36.32M-$26.16M-$35.87M-$37.65M
Free Cash Flow$120.45M$190.03M$46.68M-$365K$10.75M$112.56M$71.2M-$119.96M
Net Cash Provided By Operating Activities$151.69M$219.92M$89.02M$30.81M$47.06M$138.72M$107.07M-$82.31M
Balance sheet
8 periods
Metric2025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Total Assets$5.86B$5.9B$5.8B$5.71B$5.93B$6.75B$6.67B$6.38B
Total Debt$2.52B$2.52B$2.52B$2.52B$2.75B$2.76B$2.76B$2.56B
Cash And Cash Equivalents
Total Liabilities$3.46B$3.4B$3.33B$3.31B$3.53B$3.54B$3.48B$3.24B
Total Stockholders Equity$2.4B$2.5B$2.47B$2.4B$2.4B$3.21B$3.19B$3.13B
Key financial metrics
8 periods
Metric2025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
P/E ratio-56.05-132.11-2,117.77-19.98-3.01-82.31-123.68-29.12
P/B ratio8.034.144.073.374.333.922.454.1
P/S ratio21.9412.1712.3811.4414.617.7611.1820.14
Debt To Equity1.051.011.021.051.150.860.870.82
Free Cash Flow Yield
Financial ratios
8 periods
Metric2025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
P/E ratio
P/B ratio8.034.144.073.374.333.922.454.1
P/S ratio21.9412.1712.3811.4414.617.7611.1820.14
Return On Equity-3.58%-0.78%-0.05%-4.22%-35.99%-1.19%-0.50%-3.52%
Debt To Equity

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
Pe
-95.69
multipleSep 4, 2026
Pb
8.29
multipleSep 4, 2026
Revenue Growth Yoy
3.25
percentSep 4, 2026
EPS Growth Yoy
-350
percentSep 4, 2026
Gross Margin
69.69
percentSep 4, 2026
Operating Margin
-6.17
percentSep 4, 2026
ROE
-8.51
percentSep 4, 2026
ROIC
-4.05
percentSep 4, 2026
Debt To Equity
1.05
ratioSep 4, 2026
FCF Yield
1.78
percentSep 4, 2026
Technical indicators
Close
104.91
priceMar 20, 2026
Volume
21,562,141
volumeMar 20, 2026
Rsi14
74.07
indexMar 20, 2026
MACD
0.39
indexMar 20, 2026
MACD Signal
0.34
indexMar 20, 2026
MACD Histogram
0.05
indexMar 20, 2026
Adx14
42.93
indexMar 20, 2026
Sma50
103.02
priceMar 20, 2026
Sma200
74.25
priceMar 20, 2026
Atr14
0.37
priceMar 20, 2026
Historical Volatility
0.04
percentMar 20, 2026
Volume Ma20
3,124,641.1
volumeMar 20, 2026
Risk measures
Resilience Score
67
score_0_100Sep 4, 2026
Beta
1.44
ratioSep 4, 2026
Volatility Annual
43.05
percentSep 4, 2026
Max Drawdown
-26.5
percentSep 4, 2026
Sharpe Ratio
2.03
ratioSep 4, 2026
Var95
-2.77
percentSep 4, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

EXAS Financial Data FAQ

What is Exact Sciences Corporation's revenue?

Exact Sciences Corporation's revenue is one of the core financial data points for EXAS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Exact Sciences Corporation's revenue growing?

Revenue growth shows whether Exact Sciences Corporation is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is EXAS's EPS?

EXAS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Exact Sciences Corporation's net income?

Exact Sciences Corporation's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Exact Sciences Corporation generate?

Free cash flow shows how much cash Exact Sciences Corporation generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Exact Sciences Corporation have?

Cash and debt help frame EXAS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.